Cited by 123Dementia and Cognitive Impairment ResearchMedical Imaging Techniques and ApplicationsAdvanced MRI Techniques and Applications

PET/MR in Dementia and Other Neurodegenerative Diseases

Barthel, Henryk, Schroeter, Matthias L., Hoffmann, Karl-Titus, Sabri, Osama·2015·Seminars in Nuclear Medicine

Abstract

The spectrum of neurodegenerative diseases covers the dementias, parkinsonian syndromes, Huntington disease, amyotrophic lateral sclerosis, and prion diseases. In these entities, brain MRI is often used in clinical routine to exclude other pathologies and to demonstrate specific atrophy patterns. [18F]FDG PET delivers early and sensitive readouts of neural tissue loss, and more specific PET tracers currently in use clinically target β-amyloid plaques or dopaminergic deficiency. The recent integration of PET into MR technology offers a new chance to improve early and differential diagnosis of many neurodegenerative diseases. Initial evidence in the literature is available to support this notion. New emerging PET tracers, such as tracers that bind to tau or α-synuclein aggregates, as well as MR techniques, like diffusion-tensor imaging, resting-state functional MRI, and arterial spin labeling, have the potential to broaden the diagnostic capabilities of combined PET/MRI to image dementias, Parkinson disease, and other neurodegenerative diseases. The ultimate goal is to establish combined PET/MRI as a first-line imaging technique to provide, in a one-stop-shop fashion with improved patient comfort, all biomarker information required to increase diagnostic confidence toward specific diagnoses. The technical challenge of accurate PET data attenuation correction within PET/MRI systems needs yet to be solved. Apart from the projected clinical routine applications, future research would need to answer the questions of whether combined brain PET/MRI is able to improve basic research of neurodegenerative diseases and antineurodegeneration drug testing.

Integrity signals

Registry

Crossref · 10.1053/j.semnuclmed.2014.12.003

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Diagnosis of neurodegenerative diseases is usually based on subjective cognitive tests in combination with neuroimaging, but the current techniques are not able to successfully diagnose these diseases in their earlier stages, when the pathology is already present but does not cause symptoms yet.

    “Diagnosis of neurodegenerative diseases is usually based on subjective cognitive tests in combination with neuroimaging [131–133], but the current techniques are not able to successfully diagnose these diseases in their earlier stages, when the pathology is already present but does not cause symptoms yet.”

Cites

Flagged first, then by citations

1 of the 26 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Barthel, H., Schroeter, M. L., Hoffmann, K.-T., & Sabri, O.
Affiliations
  • University Hospital Leipzig (DE)
  • Max Planck Institute for Human Cognitive and Brain Sciences (DE)
  • Leipzig University (DE)
Corresponding author
Barthel, Henryk
Venue
Seminars in Nuclear Medicine
Publisher
Elsevier BV
Published
2015-05
Volume
45
Issue
3
Pages
224-233
ISSN
0001-2998 (ISSN-L)
OpenAlex
W1987273610
Cited by
123
References
26
Citations by year
2026: 3 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 12 · 2018: 16 · 2017: 13 · 2016: 20 · 2015: 5
FWCI
14.60
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Nuclear Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Keywords
PET/MRI, neurodegenerative diseases, dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, FDG-PET, amyloid PET tracers, tau PET tracers, diffusion tensor imaging, resting-state fMRI, arterial spin labeling, PET attenuation correction, neurodegeneration biomarkers, differential diagnosis
MeSH terms
Dementia, Humans, Magnetic Resonance Imaging, Parkinsonian Disorders, Positron-Emission Tomography, Multimodal Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review